Online inquiry

IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8565MR)

This product GTTS-WQ8565MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD47 gene. The antibody can be applied in Colorectal Cancer (CRC) Cancers (CRC) Cancers(CRC), Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_001777.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 961
UniProt ID Q08722
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ8565MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11381MR IVTScrip™ mRNA-Anti-IGF, MEDI-573(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MEDI-573
GTTS-WQ4116MR IVTScrip™ mRNA-Anti-ICAM1, BI-505(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BI-505
GTTS-WQ5095MR IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CAM-3001
GTTS-WQ14689MR IVTScrip™ mRNA-Anti-MS4A1, SCT-400(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA SCT-400
GTTS-WQ6178MR IVTScrip™ mRNA-Anti-IGF1R, CP-751871(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CP-751871
GTTS-WQ12464MR IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA NKTR-214
GTTS-WQ6733MR IVTScrip™ mRNA-Anti-EGFR, DS 992(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA DS 992
GTTS-WQ14179MR IVTScrip™ mRNA-Anti-ANGPT2, REGN-910(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA REGN-910
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW